<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="283">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05157464</url>
  </required_header>
  <id_info>
    <org_study_id>21-00823</org_study_id>
    <nct_id>NCT05157464</nct_id>
  </id_info>
  <brief_title>Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty</brief_title>
  <official_title>Losartan Use to Mitigate Arthrofibrosis Following Total Join Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Recent research has focused on methods to mitigate scar tissue formation and arthrofibrosis&#xD;
      following surgery in hopes that patients may attain maximal range of motion goals, avoid&#xD;
      manipulation and secondary surgery (i.e. revision arthroplasty), and improve their function.&#xD;
      The synovial fluid milieu has also highlighted the role of local biochemical markers that may&#xD;
      be implicated in the development of arthrofibrosis. Losartan is an angiotensin receptor&#xD;
      blocker with inhibitory effects on transforming growth factor beta (TGF-b), largely&#xD;
      implicated in tissue repair and fibrosis by way of SMAD protein signaling suppression, and&#xD;
      has been used in orthopaedic sports medicine to prevent stiffness following hip arthroscopy.&#xD;
      To date, this has not commonly been used at NYU Langone in orthopedic surgery. The purpose of&#xD;
      this study is to evaluate the efficacy of losartan use pre- and post-operatively on range of&#xD;
      motion and the incidence of manipulation under anesthesia following total knee arthroplasty.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a prospective, randomized, controlled, open label, parallel two-arm design, single-center study to compare the use of losartan in the prevention of stiffness following total knee arthroplasty.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Post-Operative Range of Motion (ROM)</measure>
    <time_frame>90 days post-surgery</time_frame>
    <description>ROM will be reported as the degree of knee flexion.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-Operative Rate of Manipulation under Anesthesia (MUA)</measure>
    <time_frame>90 days post-surgery</time_frame>
    <description>Rate of MUA will be reported as percentage of participants that require MUA.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Arthrofibrosis</condition>
  <arm_group>
    <arm_group_label>Losartan Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No additional steps in management are required for the control arm of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Losartan</intervention_name>
    <description>Patients in this group will receive Losartan 12.5mg orally twice daily beginning 2 weeks preoperatively and continuing for 4 weeks postoperatively. Losartan is an Angiotensin II Receptor Blocker currently used in the treatment of hypertension.</description>
    <arm_group_label>Losartan Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients are candidates for elective primary total knee arthroplasty for a diagnosis&#xD;
             of osteoarthritis or inflammatory arthritis.&#xD;
&#xD;
          2. Patients â‰¥18 years of age&#xD;
&#xD;
          3. Patients have been medically cleared and scheduled for surgery&#xD;
&#xD;
          4. Patients' primary care physician has verified that the patient can safely take the&#xD;
             described dose of Losartan for the duration of the study period.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any contraindications to Losartan&#xD;
&#xD;
          2. Revision surgery&#xD;
&#xD;
          3. Surgery for fracture, infection, or malignancy&#xD;
&#xD;
          4. Patients with a diagnosis of post-traumatic arthritis&#xD;
&#xD;
          5. Bilateral, simultaneous surgery&#xD;
&#xD;
          6. Patients already taking an ACE-inhibitor or Angiotensin receptor blocker for&#xD;
             hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Rozell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Waren</last_name>
    <phone>212-598-6245</phone>
    <email>Daniel.waren@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Daniel Waren</last_name>
      <email>Daniel.waren@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Joshua Rozell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 2, 2021</study_first_submitted>
  <study_first_submitted_qc>December 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 15, 2021</study_first_posted>
  <last_update_submitted>December 2, 2021</last_update_submitted>
  <last_update_submitted_qc>December 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Total Knee Arthroplasty (TKA)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Losartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices) will be available upon reasonable request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data will have access upon reasonable request. Requests should be directed to daniel.waren@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

